Sanofi personalizes cancer treatment and accelerates drug discovery using advanced AI
Sanofi, a global pharmaceutical leader based in France, is leveraging advanced AI and Microsoft Azure technologies to transform two core areas: cancer treatment optimization and drug discovery acceleration. In partnership with AI-driven firms like Owkin, BioMap, and Exscientia, Sanofi employs large-scale federated learning, multimodal medical data analysis, and protein large language models (LLMs) to: 1) discover prognostic biomarkers and novel therapeutic targets in aggressive cancer subtypes; and 2) automate protein engineering and minor molecule candidate discovery for new drugs. Their Responsible AI framework guides transparent, ethical implementation. While most AI-enabled pipelines are recently launched or ongoing, the company has announced faster drug identification timelines, expansion into immunology, and progress of novel therapeutic agents to preclinical phases—all enabled by secure, scalable Azure cloud services. The implementation involves collaborations and integration between proprietary data, cloud AI services, and advanced analytics for precision medicine.
Reported outcomes
Strategic outcomes
Primary read
Use case focus
Showing 3 of 4
- 1Personalized oncology treatment optimization agent
- 2AI-driven drug discovery automation platform
- 3Federated learning for clinical biomarker identification
- Difficulty personalizing treatment for aggressive cancers (e.g., triple-negative breast cancer) with high mortality and resistance to standard therapies
- Traditional drug discovery takes 12-15 years, delaying life-saving treatments and resulting in patient deaths
- Lack of effective tools to analyze complex, multimodal patient data for biomarker and therapeutic target identification
- Need to identify suitable proteins/targets efficiently to expedite R&D pipelines
- Requirement to balance AI innovation with risk management and regulatory compliance
- Used federated learning and multimodal data analysis with AI models to detect new biomarkers and predict treatment response (cancer care)
- Partnered with companies like Owkin, BioMap, Exscientia to access and develop AI-driven platforms and protein LLMs
- Leveraged Microsoft Azure and compatible AI cloud services for secure, scalable compute and integration of proprietary data
- Established Responsible AI principles to ensure ethical, robust, and transparent implementation
- Automated workflows from biomarker discovery to molecule design, reducing time-to-market for drug candidates
- Enabled identification of novel gene/biomarker targets for precision oncology
- Personalized patient stratification and tailored treatment protocols in cancer care
- Accelerated pipeline for up to 15 new minor molecule drug candidates in oncology and immunology
- Announced expansion of AI-driven medicine pipeline to new areas like immunology
- Produced new therapeutic agents reaching preclinical and IND-enabling development phases
Architecture
Sanofi integrates advanced AI platforms (from Owkin, BioMap, and Exscientia) into its drug discovery and clinical trial optimization processes, leveraging federated learning on multimodal medical data via Microsoft Azure cloud. The process involves data access and curation, AI-driven patient and target characterization, and collaboration on secure, scalable Azure cloud infrastructure. Proprietary data and external AI models interconnect, automating workflows across biomarker detection, novel molecule candidate design, and patient stratification.
Implementation partners3
Sources & evidence1
The same organization appears in newer AI deployment evidence.
- Same organization re-documented as recently as 2026.
- Cited source last checked Jun 1, 2026 — ok (0/1 broken).
Measures whether this deployment's public evidence persists — not whether the system is still in production.
AI-generated summary. Verify important details with the linked sources before relying on this case.